Philanthropists Eli & Edythe Broad announce second $100M gift to support Broad Institute

November 30, 2005

Cambridge, MA, and Los Angeles, CA, Nov. 30, 2005 - Only eighteen months after the launch of the Broad Institute of MIT and Harvard, Los Angeles-based philanthropists Eli and Edythe Broad announced today that they are doubling their founding gift to the Institute from $100 million to $200 million. The Broads' gift is the largest ever given to support a joint endeavor combining the strengths of two great universities - Harvard and MIT. With the Broads' first $100 million gift having been made to MIT, the second $100 million gift will now be made through Harvard. The combined gift will be given as $20 million per year over ten years.

"Edye and I have been impressed by the tremendous progress already made by the scientists at the Broad Institute and by the success of this new model for collaborative science involving Harvard and MIT." said Eli Broad, founder and chairman of the Broad Foundations. "We are making this gift because we believe that the next generation of young scientists has the vision and ability to transform medicine."

"Our gift will allow the Broad Institute to create new capabilities that will allow it to take on important new challenges," added Mr. Broad. "We hope others will join us in supporting this unique and powerful venture."

The Broad Institute's mission is to fulfill the promise of genomics for medicine. It aims to empower creative scientists to construct new powerful tools for genomic medicine, to make them accessible to the global scientific community, and to apply them to the understanding and treatment of disease. The Broad Institute is a new type of biomedical research institute announced in 2003 and launched in 2004 by an unprecedented collaboration of the Massachusetts Institute of Technology, Harvard University, Harvard affiliated hospitals, and the Whitehead Institute for Biomedical Research.

"Eli and Edythe Broad's vote of confidence, expressed through this generous gift, is a tribute to the work of hundreds of young scientists who have come together under this unique collaboration," said Dr. Eric Lander, founding director of the Broad Institute. "The Broad Institute's scientists have already made major advances in cancer, medical genetics, chemical biology, infectious disease and other fields. The Broads' unrestricted support helps a remarkable generation seize the opportunities ahead." The Broad Institute's annual budget of $100 million is derived largely from traditional peer-reviewed scientific grants, but the Broads' gift will allow the Institute to pursue new directions and initiatives.

"The promise of genomic medicine to diagnose, treat, and potentially cure diseases that affect millions can be more rapidly achieved through collaboration and partnership," said Harvard President Lawrence H. Summers. "The Broad Institute, thanks to Eli and Edye Broad's continuing generous support, has become a model for the way we think about, organize and conduct research. By bringing together different scientific disciplines, the Institute will allow us to increase our understanding of the human genome and turn this knowledge into treatments and cures for diseases more rapidly."

"The mission of the Broad Institute draws on the extraordinary strengths in the Boston/Cambridge area, with its world-leading institutions and scientific minds and resources. The vision of the Broad reaches across the frontiers of scientific, technological and medical research and sets out new structures for collaborative work," said Susan Hockfield, president of MIT. "We continue to be profoundly grateful to Eli and Edye Broad for their visionary commitment to this important work and for their extraordinary leadership as philanthropists."

"My hat's off to Eli and Edythe Broad. Their extraordinary generosity will accelerate discovery and thereby lay the foundations for genome-powered medicine," said David C. Page, Director of the Whitehead Institute. "The Broad's gift led to the forging of a groundbreaking partnership among Harvard, MIT, the Harvard hospitals, and Whitehead, and a glorious new institute is the result. We at Whitehead look forward to continuing and expanding collaborations with Broad scientists."

The Broad Institute involves a world-class faculty including a total of 60 core and associate members, with appointments at one of the Harvard or MIT based institutions. They collaborate through scientific programs based at the Broad to identify and tackle important projects. The activities range across biomedical science including:

  • chemical biology (using chemistry to probe biological systems and to identify potential therapeutics),
  • genome analysis studies (including sequencing and analysis of mammals and microbes to identify the functions encoded in human DNA),
  • medical and population genetics (including defining the genetic variation in the human population and using it to find the basis of diseases such as diabetes or psychiatric disorders),
  • cancer (ranging from mapping the molecular pathways of different cancer types to identifying novel compounds to alter tumor development and growth).
  • infectious disease (ranging from understanding the genetic variability of infectious agents to identifying new therapeutics).

    Broad scientists have helped enable these studies by playing a leading role in creating genomic tools that can be used by the entire biomedical community. Broad scientists led the recently completed international effort to create a catalog of human genetic variation called the Haplotype Map ("HapMap"). They are also leading an international collaboration to make a complete library of RNA interference (RNAi) against every human and mouse gene. (For further examples of current initiatives and programs, go to www.broad.mit.edu).

    "The intellectual community of the Broad Institute has made possible our work in understanding the basic workings of malaria," said Dr. Dyann Wirth, professor of infectious diseases at the Harvard School of Public Health and associate member of the Broad Institute. "We could never have done this alone."

    "Work in my laboratory on the Achilles' heels of cancer has flowed directly from collaborations at the Broad Institute," said Dana-Farber Cancer Institute's Dr. William Hahn, assistant professor of medicine at Harvard Medical School and an associate member of the Broad Institute. Hahn has been a leader of the Broad-based RNAi Consortium. "The unique energy and organization of the Broad community is accelerating progress in many labs."

    A new Broad Institute building, located at 7 Cambridge Center in Kendall Square in Cambridge, is scheduled for completion in the early spring of 2006. The expansion from the Institute's current nearby location at 320 Charles Street along with the new gift from the Broads will allow Broad scientists to undertake additional exciting and critical scientific studies they have identified as priorities for furthering the understanding of human biology and disease.

    The new gift will be provided through The Broad Foundations, a Los Angeles-based venture philanthropic organization established by Eli and Edythe Broad. (www.broadfoundation.org).

    Contacts:
    Harvard University:
    B.D. Colen
    617-495-7821
    bd_colen@harvard.edu

    MIT:
    Elizabeth Thomson
    617-258-5402
    thomson@mit.edu

    Broad Institute:
    Fintan Steele
    617-324-1698
    fsteele@broad.mit.edu

    Broad Institute of MIT and Harvard

    Related Cancer Articles from Brightsurf:

    New blood cancer treatment works by selectively interfering with cancer cell signalling
    University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

    UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
    A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

    Breast cancer treatment costs highest among young women with metastic cancer
    In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

    Cancer mortality continues steady decline, driven by progress against lung cancer
    The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

    Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
    Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

    Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
    The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

    Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
    Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

    More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
    An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

    New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
    Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

    American Cancer Society outlines blueprint for cancer control in the 21st century
    The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

    Read More: Cancer News and Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.